Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Applied Therapeutics regarding the New Drug Application (NDA) for govorestat for the treatment of classic ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

Dear Readers, the magical stage musical of the beloved “Mary Poppins”, currently playing at the 5th Avenue Theatre, may not ...

UBS analyst Colin Bristow downgraded Applied Therapeutics (APLT) to Neutral from Buy with a price target of $2, down from $13.Don't Miss our ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75 ...

A village hall could soon be getting a new roof and solar panels. David Smith has applied for planning permission for the work at Stoke Ferry Village Hall, near Downham Market. The application states ...

The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.

Applied Therapeutics' stock plummeted 75 percent after the Food and Drug Administration (FDA) rejected approving govorestat ...

Fintel reports that on November 29, 2024, RBC Capital downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from ...